Jane Street
ADCT icon

Jane Street’s ADC Therapeutics ADCT Stock Holding History

Jane Street’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,700
Closed -$47.6K – 11407
2026
Q1 		$47.6K Buy
+12,700
New +$50.1K ﹤0.01% 10986
2025
Q3 		– Sell
-14,500
Closed -$38.9K – 10667
2025
Q2 		$38.9K Buy
+14,500
New +$30.5K ﹤0.01% 9242
2024
Q2 		– Sell
-10,800
Closed -$48.5K – 9248
2024
Q1 		$48.5K Buy
+10,800
New +$39.8K ﹤0.01% 8748
2021
Q3 		– Sell
-16,000
Closed -$390K – 9834
2021
Q2 		$390K Buy
+16,000
New +$371K ﹤0.01% 7705

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street's ADCT Position: Q2 2026 in Review

Jane Street reduced its ADC Therapeutics (ADCT) stake by 57% in Q2 2026, selling an estimated $236K and leaving 61,267 shares worth $65.6K. The position accounts for ﹤0.01% of the portfolio, ranked #10815.

Jane Street first reported a position in ADCT in Q1 2023 and has held it in 10 quarters since. The position peaked at $1.95M in Q3 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Jane Street held 61,267 shares of ADC Therapeutics worth $65.6K as of Q2 2026.
  • Jane Street sold 80,796 ADC Therapeutics shares in Q2 2026, an estimated $236K.
  • ADC Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10815 holding.
  • Jane Street first reported a position in ADC Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • Jane Street's ADC Therapeutics position peaked at $1.95M in Q3 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.